Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares are up during Friday’s premarket session as the company recently reported its fourth-quarter and full-year financial results, highlighting significant developments in its product pipeline.

Tonix Pharmaceuticals’ Sales Almost Doubled

Tonix Pharmaceuticals reported a fourth-quarter loss of $3.98, missing the consensus loss of $3.16. Sales reached $5.39 million, beating the consensus of $2.88 million.

Tonix Pharmaceuticals announced that since its launch in November 2025 through February 2026, more than 1,500 healthcare providers have prescribed Tonmya (cyclobenzaprine HCl sublingual tablets).

Approximately 2,500 patients have initiated treatment with the fibromyalgia drug, and cumulative prescriptions totaled approximately 4,200.

In August 2025, the U.S. FDA approved Tonmya for fibromyalgia in adults, making it the first new prescription medicine approved for this indication in more than 15 years.

The company is prioritizing expanding payer engagement and establishing contracts with ...